CytomX Therapeutics, Inc.

CytomX Therapeutics Misses on EPS, Stock Up 2.63%

CytomX Therapeutics reported a loss per share of $0.64, but the stock reacted positively, increasing by 2.63%. This suggests that investors may have been expecting a worse outcome or are optimistic about future developments, despite the lack of revenue figures and guidance. The absence of management commentary leaves some uncertainty about the company's direction.